Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives $27.83 Consensus Target Price from Analysts

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have been assigned a consensus recommendation of “Hold” from the six analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $27.8333.

A number of equities research analysts have commented on the stock. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday. They set a “market perform” rating for the company. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday. The Goldman Sachs Group cut their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Finally, Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a report on Wednesday, July 15th.

Insider Buying and Selling at Kestra Medical Technologies

In other news, insider Brian Daniel Webster sold 15,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $20.81, for a total transaction of $312,150.00. Following the sale, the insider owned 395,467 shares of the company’s stock, valued at approximately $8,229,668.27. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Hedge funds have recently added to or reduced their stakes in the stock. Seven Grand Managers LLC purchased a new position in shares of Kestra Medical Technologies in the 4th quarter valued at $2,652,000. Eventide Asset Management LLC lifted its position in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after acquiring an additional 65,288 shares during the last quarter. Summit Partners Public Asset Management LLC acquired a new position in Kestra Medical Technologies in the fourth quarter valued at $9,282,000. Jennison Associates LLC boosted its stake in Kestra Medical Technologies by 15.0% in the fourth quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock valued at $5,817,000 after acquiring an additional 28,573 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of Kestra Medical Technologies by 34.9% during the fourth quarter. UBS Group AG now owns 270,058 shares of the company’s stock worth $7,162,000 after purchasing an additional 69,908 shares during the last quarter.

Kestra Medical Technologies Stock Performance

Shares of Kestra Medical Technologies stock opened at $22.24 on Friday. The business has a 50-day simple moving average of $22.32 and a 200-day simple moving average of $22.63. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. Kestra Medical Technologies has a one year low of $14.10 and a one year high of $30.00. The company has a market cap of $1.30 billion, a PE ratio of -9.19 and a beta of 0.47.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The firm had revenue of $28.64 million during the quarter. On average, equities research analysts forecast that Kestra Medical Technologies will post -2.3 EPS for the current fiscal year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.